In the latest trading session,, 1.21 million Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares changed hands as the company’s beta touched 0.24. With the company’s most recent per share price at $42.25 changing hands around $2.31 or 5.78% at last look, the market valuation stands at $6.72B. IONS’s current price is a discount, trading about -23.88% off its 52-week high of $52.34. The share price had its 52-week low at $23.95, which suggests the last value was 43.31% up since then. When we look at Ionis Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 2.13 million shares, with the 3-month average coming to 1.74 million.
Analysts gave the Ionis Pharmaceuticals Inc (IONS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 1 out of 14 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended IONS as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) trade information
Instantly IONS is in green as seen in intraday trades today. With action 5.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -11.35%, with the 5-day performance at 5.62% in the green. However, in the 30-day time frame, Ionis Pharmaceuticals Inc (NASDAQ:IONS) is 23.86% up. Looking at the short shares, we see there were 14.23 million shares sold at short interest cover period of 10.23 days.
The consensus price target for the stock as assigned by Wall Street analysts is 55, meaning bulls need an upside of 23.18% from its recent market value. According to analyst projections, IONS’s forecast low is 28 with 77 as the target high. To hit the forecast high, the stock’s price needs a -82.25% plunge from its current level, while the stock would need to tank 33.73% for it to hit the projected low.
The 2025 estimates are for Ionis Pharmaceuticals Inc earnings to decrease by -2.97%, but the outlook for the next 5-year period is at 23.06% per year.
IONS Dividends
Ionis Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Apr-30.
Ionis Pharmaceuticals Inc (NASDAQ:IONS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.81% of Ionis Pharmaceuticals Inc shares while 108.13% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 109.02%. There are 108.13% institutions holding the Ionis Pharmaceuticals Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 15.0008% of the shares, roughly 21.89 million IONS shares worth $1.04 billion.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.4861% or 13.85 million shares worth $659.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund . With 7.65 shares estimated at $326.57 million under it, the former controlled 4.81% of total outstanding shares. On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund held about 3.60% of the shares, roughly 5.73 shares worth around $244.7 million.
